Search ARM

Q2 2018 Data Report


This report assembles a global sector overview, including details on financings, partnerships and other deals, clinical trial information, major clinical data events, and ARM’s current legislative and regulatory priorities.

Global Landscape

875+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total Q2 2018 Global Financings

Total Global Financing

$4.1 Billion

164%

Increase from Q2 2017

79%

Increase year-over-year
$7.9B Raised YTD 2018

Gene & Gene-modified
Cell Therapy

$2.7 Billion

 124%

Increase from Q2 2017

133%

Increase year-over-year
$5.8B raised YTD 2018

Cell Therapy

$2.2 Billion

416%

Increase from Q2 2017

83%

Increase year-over-year
$4.2B raised YTD 2018

Tissue Engineering

$421 Million

526%

Increase from Q2 2017

25%

Increase year-over-year
$784M raised YTD 2018

Total Global Financings by Type, by Year

977

Clinical trials underway
worldwide by the end of Q2 2018

PH. 1

324

PH. 2

560

PH. 3

93

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q2 2018

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q2 2018

Report Infographics